“The North America dermatology devices market is estimated to grow at a CAGR of 10.0% from 2014 to 2019. The growth of this market is driven by factors such as technical advancements, rising incidences of skin disorders, increasing awareness about aesthetic procedures, growing prevalence of skin cancer, low cost/utility ratio, and increasing investments. However, competitive pricing, huge untapped population, and high threats from substitutes hamper the growth of the North American dermatology devices market. Moreover, continuous technological up-gradations create new growth opportunities for the North American dermatology devices market in these regions.
In this report, the market has been broadly classified on the basis of types. Depending on types, the market is further classified into dermatology treatment devices and dermatology diagnostic devices. The dermatology treatment devices market segment accounted for the largest market share of 95.7% of the North America dermatology devices market. Factors such as the increasing prevalence rates of indications and increasing demand for devices with less downtime drive the growth of this market.
The North American dermatology devices market is a competitive one with a number of market players. As of 2014, the U.S. dermatology devices market was estimated to be dominated by Heine Optotechnik (Germany), Optomed Oy (Finland), FotoFinder Systems (Germany), Michelson diagnostics (U.K.), Genesis Biosystems (U.S.), Ellipse A/S (Denmark), Alma Lasers (Israel), Palomar Technologies (U.S.), GE Healthcare (U.K.), and Philips Healthcare (the Netherlands), Verisante Technology, Inc. (Canada), MELA Sciences, Inc. (U.S.), Verisante Technology, Inc. (U.S.), Welch Allyn (U.S.), Carl Zeiss Meditec, Inc. (U.S.), Hitachi (Japan), Leica Microsystems (Germany), Olympus (Japan), GE Healthcare (U.K.), Phillips Healthcare (the Netherlands), Toshiba Medical Systems (Japan), and Siemens Medical Systems (Germany). New product launches &...